Urban Outfitters: Conference Takeaways

Urban Outfitters: Conference Takeaways

Lessons learned from 4Q stumble at UO/Anthro

Consumer Discretionary

Highlights From Procter & Gamble at BofAML’s Consumer Conference

BofAML hosted meetings with P&G in conjunction with its Consumer Conference

Guess? Delivered A 4th Quarter Miss On The Top to Bottom Line

Jefferies is encourages by mgmt's commitment to store footprint reductions and rent negotiations domestically while diverting capital to Europe/Asia where growth and profitability are more visible and sustainable

Tesla Kicksoff Deliveries of Model S and X 100D

The 100D Models have bigger range than all the other Tesla Inc (TSLA) vehicles

Takeaways from Expedia Meeting with Oppenheimer

Oppenheimer hosted two days of well attended investor meetings with EXPE's investor relations team

Amazon.com Continues To Drive Majority of E-commerce Market Growth

Wedbush estimate AMZN grew its e-commerce in the US by ~25% in 2016, accounting for the majority of the overall e-commerce market growth in the US and raising its share of the e-commerce market to ~50%

The Narrative For Tiffany & Co Shares Might Now Be Shifting Meaningfully

A well-regarded activist investor recently assumed a stake in TIF and seemingly influenced a significant management and board repositioning at the chain. Headwinds persist for TIF


Oracle Corporation: Good Against Low Expectations Says BMO

Oracle grew the operating income margin (42.5% vs. 42.4% in the February 2016 quarter), and grew operating income dollars by 3.2% y/y

Google Is Reportedly Working on 3 Successors to Its Pixel Phone

It seems that the search engine company is planning to surprise its users by launching three new smartphone this year

Netflix to Start Producing Mobile Specific Cuts of Original Series to Satisfy Growing Market

The company is willing to explore creating different cuts accommodating for smaller screens

Oracle Corporation: Raising FV, But Won't Likely Be Viewed The Same As Microsoft Corporation

MKM thinks MSFT is being rewarded for Azure's unique competitive advantage as one of only three hyperscale clouds, generating net growth in workloads, vs. ORCL's largely fee-oriented growth for existing workloads

GoPro: Raising EPS Estimates On Cost Cuts; No Change To Revenue Estimates

While there are some working capital quarterly fluctuations, the firm now assumes slightly positive FCF in 2017 and 2018 for the year

GoPro Inc (GPRO) Q1 Revenue to Meet Higher End of Guidance, Cutting 270 Jobs

GoPro’s announced restructuring will not impact its roadmap for new hardware and software products


Diamond Offshore Drilling Wins in Battle with Petrobras Over Ocean Valor

The drilling contract had been set to conclude in October 2018, and Wednesday’s panel of three judges’ decision overrides Petrobras’ appeal of a judge’s Sept 13 injunction keeping the rig on contract

Occidental Petroleum Corporation (OXY): Shining a Light on The Permian

BAML thinks this perception is wrong; moreover assuming the Permian is self-funding at $50 oil, the firm suggests any drag on growth capital is eliminated

Credit Suisse Upgraded Occidental Petroleum Corporation (OXY) into its

As Credit Suisse rolls over the model, the firm's TP rises to $79/sh from $77/sh

Apache Corporation (NYSE:APA) Management Meeting Highlights with RBC

There was genuine management confidence in Alpine High, based on proprietary information such as 3D seismic and data from 30+ wells drilled so far

BMO Analyzes Marathon Oil Corporation's (MRO) Delaware and OSM Deal Analysis

Marathon's $1.1B acquisition of BC Operating expands its U.S. unconventional footprint to include the northern Delaware Basin


Kite Pharma: NHS Analysis Determines a £530K Price Tag Reasonable for CAR T Therapy

The study was conducted for young ALL and determined a price of £530K ($649K) was justified

Canaccord on Kite Pharma Inc (KITE)

Canaccord believes the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit

Jefferies on Gilead Sciences, Inc. (NASDAQ:GILD)

U.S. sales for 1Q17 look to be tracking in line with Jefferies' $800M estimate and $790M consensus

Ackman's Exit Sends Valeant Pharmaceuticals Intl Inc (VRX) Shares to Greater Than 7-Year Low

Valeant Pharmaceuticals’ recent loss of Bill Ackman’s investment serves as a point of caution for the investors going forward

Jefferies on Biotechnology: Celgene Corporation (NASDAQ:CELG)

The results were favorable for the up and coming drug with a differentiated MOA